Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clarification 06 July 2023

Investigating the origins of recent pharmaceutical innovation

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 781-782 (2023)


Updates & Corrections

  • Clarification 06 July 2023: It has been clarified in Table 1 that three of the top 20 biopharma companies (Amgen, Biogen and Gilead Sciences) are defined as biotech companies founded after 1976 in the analyses presented in the article, such as those shown in Figure 1b and 1c. For full details of how each drug is assigned on the basis of company type, see Supplementary Table 2.

Supplementary Information

  1. Supplementary information
  2. Supplementary Fig. 1

Competing Interests

A.S. and O.G. declare no competing interests. M.H. is an employee of Novartis and a former employee of Roche and Sanofi. D.H. is a former employee of Roche and Novartis. A.D. is an employee of Johnson & Johnson. This study did not receive external funding and was undertaken independently.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links